SM
BCLI

SG3 Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

SG3 Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-667
Closed -$169K – 1015
2020
Q3 		$169K Buy
+667
New +$137K 0.01% 749

Other funds holding BCLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SG3 Management's BCLI Position: Q4 2020 in Review

SG3 Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2020, closing a stake of 667 shares — an estimated $169K sold.

SG3 Management first reported a position in BCLI in Q3 2020 and held it in 1 quarter. The position peaked at $169K in Q3 2020. 90 funds tracked by Wall St. Rank hold BCLI as of Q4 2020.

  • SG3 Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2020 after selling out during the quarter.
  • SG3 Management sold 667 BRAINSTORM CELL THERAPUTC shares in Q4 2020, an estimated $169K.
  • SG3 Management first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2020 and held it in 1 quarter.
  • SG3 Management's BRAINSTORM CELL THERAPUTC position peaked at $169K in Q3 2020.
  • 90 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2020.

Based on SG3 Management's 13F filing for Q4 2020, filed 16 Feb 2021.